UFP Technologies UFPT
- Market cap
- $2.3B
- PE
- 31.9×
- 10y median 25.6×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.6×
- EV/EBIT
- 24.9×
- Revenue, 12 months
- $631.6M
- +7% on a year ago
- Net margin
- 11.4%
- Free cash flow yield
- n/m
- not a meaningful number
UFP Technologies trades at 31.9× trailing earnings, pricier than 79% of the last ten years. Revenue was $631.6M over the last twelve months, up 7% on a year earlier with a 11% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $100.8M+4% | $101.5M+11% | $105M+7% | $110.2M+10% | $145.2M+44% | $144.1M+42% | $148.1M+41% | $151.2M+37% | $154.6M+7% | $148.9M+3% | $154.2M+4% | $174M+15% | |
| Cost of revenue | $73M+2% | $75.4M+11% | $74.9M+9% | $77.1M+10% | $103.6M+42% | $102M+35% | $106M+42% | $107.6M+40% | $111.8M+8% | $106.9M+5% | $109.8M+4% | $123M+14% |
| Gross profit | $27.8M+9% | $26.1M+12% | $30.1M+5% | $33M+11% | $41.5M+50% | $42.1M+61% | $42.2M+40% | $43.5M+32% | $42.7M+3% | $42M−0% | $44.4M+5% | $50.9M+17% |
| SG&A | $12.5M+6% | $13.1M+10% | $13.9M+7% | $13.9M+13% | $15.8M+27% | $18.6M+42% | $18.7M+35% | $18.7M+34% | $19.1M+21% | $21M+13% | $21M+12% | $22.8M+22% |
| $15M−42% | $12.7M+17% | $15.9M+24% | $18M+5% | $24.8M+65% | $22.3M+75% | $23.1M+45% | $24.3M+36% | $23.4M−6% | $21.5M−3% | $23.4M+1% | $28.1M+16% | |
| Interest expense | $933K+12% | $755K−13% | $631K−27% | $577K−47% | $3.5M+273% | $3.4M+347% | $2.8M+345% | $2.7M+363% | $2.4M−31% | $1.9M−43% | $1.7M−38% | $1.7M−36% |
| Pre-tax income | $14.1M−44% | $11.9M+22% | $15.3M+29% | $17.4M+9% | $21.2M+50% | $19.1M+61% | $20.3M+32% | $21.6M+25% | $21.1M−1% | $19.5M+2% | $21.6M+7% | $26.4M+22% |
| $2.4M−57% | $284K−78% | $2.6M+23% | $3.8M−7% | $4.9M+99% | $2.7M+859% | $3.1M+17% | $4.4M+16% | $4.7M−4% | $2M−28% | $4.1M+33% | $5.6M+25% | |
| Net income | $11.7M−40% | $11.6M+37% | $12.7M+30% | $13.6M+14% | $16.4M+40% | $16.4M+41% | $17.2M+35% | $17.2M+27% | $16.4M+0% | $17.6M+7% | $17.5M+2% | $20.9M+21% |
| $1.52−41% | $1.50+38% | $1.64+29% | $1.75+13% | $2.11+39% | $2.09+39% | $2.21+35% | $2.21+26% | $2.11+0% | $2.25+8% | $2.24+1% | $2.68+21% | |
| 7.7M+1% | 7.7M−1% | 7.7M+1% | 7.8M+1% | 7.8M+1% | 7.9M+2% | 7.8M+1% | 7.8M+0% | 7.8M+0% | 7.9M+0% | 7.8M+0% | 7.8M+0% |
Net income: 11 periods, Q1 FY12 to Q2 FY15: not printed by the filing, worked out from its own lines.
EPS, diluted: 13 periods, Q4 FY10 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest UFP Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| ATRCAtriCure | $3B | 281× | 58.4× | 5.3× | +14% | 1.9% | |
| WRBYWarby Parker | $3.2B | 370× | 366× | 3.5× | +11% | 0.8% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| NVSTEnvista | $3.8B | 40.7× | 27.9× | 1.3× | +12% | 3.3% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| ICUIICU Medical | $4.2B | 141× | 57.8× | 1.9× | −9% | 1.4% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| BMIBadger Meter | $4.4B | 35.3× | 47.6× | 5.0× | −2% | 14.3% | |
| Peer median | $2.5B | 36.2× | 50.5× | 2.2× | +9% | 4.3% |
More on UFP Technologies
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .